These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33289960)

  • 1. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
    Lewis JH; Gelderblom H; van de Sande M; Stacchiotti S; Healey JH; Tap WD; Wagner AJ; Pousa AL; Druta M; Lin CC; Baba HA; Choi Y; Wang Q; Shuster DE; Bauer S
    Oncologist; 2021 May; 26(5):e863-e873. PubMed ID: 33289960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
    Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
    Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
    Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
    Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 6. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience.
    Dharmani C; Wang E; Salas M; McCabe C; Diggs A; Choi Y; Jiang J; Keedy VL
    Future Oncol; 2022 Apr; 18(13):1595-1607. PubMed ID: 35105158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT).
    Tap W
    Future Oncol; 2020 Sep; 16(25):1875-1878. PubMed ID: 32755241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor.
    Lin F; Jacqueline Kwong W; Pan I; Ye X; Dai D; Tap W
    Oncologist; 2024 Apr; 29(4):e535-e543. PubMed ID: 37874926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TURALIO
    Dharmani C; Fofah O; Fallon M; Rajper AW; Wooddell M; Salas M
    Future Oncol; 2024; 20(33):2559-2564. PubMed ID: 39023446
    [No Abstract]   [Full Text] [Related]  

  • 10. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
    Gelderblom H; de Sande MV
    Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.
    Yin O; Zahir H; French J; Polhamus D; Wang X; van de Sande M; Tap WD; Gelderblom H; Wagner AJ; Healey JH; Greenberg J; Shuster D; Stacchiotti S
    CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1422-1432. PubMed ID: 34585528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
    Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
    J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team.
    McCabe C; Wright H; Polson K; Wagner AJ
    Orphanet J Rare Dis; 2023 Oct; 18(1):313. PubMed ID: 37805596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
    Monestime S; Lazaridis D
    Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
    Healey JH; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; van de Sande M
    Clin Orthop Relat Res; 2023 Jan; 481(1):107-116. PubMed ID: 36001000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
    Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenosynovial giant cell tumor-diffuse type, treated with a novel colony-stimulating factor inhibitor, pexidartinib: initial experience with MRI findings in three patients.
    Helming A; Hansford B; Beckett B
    Skeletal Radiol; 2022 May; 51(5):1085-1091. PubMed ID: 34586485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.
    Van De Sande M; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; Healey JH
    Acta Orthop; 2021 Aug; 92(4):493-499. PubMed ID: 33977825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.